GlassScriptPhysician profile
Matthew C Simmons
NPI 1467747840
$4,642.63
in general payments reported to CMS, 2019-2025
46 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $498 · 2021: $846 · 2022: $506 · 2023: $906 · 2024: $1,066 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,539.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $880.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $601.90 | 2020-2025 | Ubrelvy, Qulipta, Mavyret |
| Lilly USA, LLC | $468.83 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.20 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $239.09 | 2019-2024 | Belsomra, Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $224.90 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $191.94 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $149.51 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $143.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $106.38 | 2020-2021 | |
| Glaxosmithkline, LLC. | $105.70 | 2019-2025 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $88.26 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.00 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $72.35 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.97 | 2021-2025 | Jardiance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.